Results 51 to 60 of about 307,974 (304)

Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in doberman pinschers with preclinical dilated cardiomyopathy (the PROTECT study) [PDF]

, 2012
<p>Background: The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported.</p> <p>Hypothesis: That chronic oral administration of pimobendan to Dobermans with ...
Boswood, A., Braz-Ruivo, L., Culshaw, G.J., Dukes-McEwan, J., Estrada, A., French, A.T., Gordon, S.G., Loureiro, J., O'Grady, M.R., O'Sullivan, M.L., Oyama, M.A., Patteson, M., Smith, A., Summerfield, N.T., Watson, P.J., Willis, R.   +15 more
core   +3 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. [PDF]

, 2018
Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development.
Carlson, Daniel F, Coutts, Alexander W, Dahiya, Sonika, Dombi, Eva, Fahrenkrug, Scott C, Fisher, James, Giovannini, Marco, Gutmann, David H, Isakson, Sara H, Kirstein, Mark N, Largaespada, David A, Messiaen, Ludwine, Moertel, Christopher L, Pluhar, G Elizabeth, Ratner, Nancy, Rizvi, Tilat, Rizzardi, Anthony E, Stemmer-Rachamimov, Anat O, Vitte, Jeremie, Watson, Adrienne L, Widemann, Brigitte C, Williams, Kyle B   +21 more
core   +2 more sources

Reciprocal control of viral infection and phosphoinositide dynamics

FEBS Letters, EarlyView.
Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley   +1 more source

Synergistic drug combinations from electronic health records and gene expression. [PDF]

, 2016
ObjectiveUsing electronic health records (EHRs) and biomolecular data, we sought to discover drug pairs with synergistic repurposing potential. EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including ...
Chen, William, Daugherty, Aaron C, Desai, Manisha, Farrington, Carl, Gomez, Scarlett L, Hastie, Trevor, Kenkare, Pragati, Kurian, Allison W, Lim, Michael, Low, Yen S, Mathur, Maya, Radin, Andrew A, Schroeder, Elizabeth A, Seto, Tina, Shah, Nigam H, Sirota, Marina, Sledge, George W, Thompson, Caroline A, Weber, Susan, Yu, Peter P   +19 more
core   +2 more sources

Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?

FEBS Letters, EarlyView.
This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes, Guilherme M. Azevedo, Amanda P. Barcellos, Diana Bahia   +3 more
wiley   +1 more source

Rapid Quantification of Ceftobiprole in Human Plasma and Cerebrospinal Fluid by LC-MS/MS and Its Application in Patients with Central Nervous System Infections

Molecules
Ceftobiprole is a fifth-generation beta-cephalosporin with high inter-individual pharmacokinetic variability in critically ill patients. However, data on its pharmacokinetics and central nervous system (CNS) penetration are limited.
Sabahat Ablimit, Wanzhen Li, Mengting Chen, Jing Zhang, Nanyang Li, Yaxin Fan, Muyassar Yasen, Mubarak Iminjan, Beining Guo   +8 more
doaj   +1 more source

Drug screening model meets cancer organoid technology

Translational Oncology, 2020
Tumor organoids inherit the genomic and molecular characteristics of the donor tumor, which not only bridge the gap between genome and phenotype but also circumvent the disadvantages such as genetic information change by using 2D cell lines and the mouse-
Chen Liu, Tianyu Qin, Yuhan Huang, Yuan Li, Gang Chen, Chaoyang Sun   +5 more
doaj   +1 more source

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. [PDF]

, 2016
PurposeTo determine the maximum tolerated dose (MTD), toxicities, and pharmacodynamics effects of sirolimus combined with oral metronomic topotecan and cyclophosphamide in a pediatric population.Materials and methodsPatients who were 1 to 30 years of age
Allen, Shelly, DuBois, Steven G, Gustafson, W Clay, Hollinger, Fabienne, Karski, Erin E, Long-Boyle, Janel R, Matthay, Katherine K, Nasholm, Nicole M, Shiboski, Stephen, Vo, Kieuhoa T   +9 more
core   +1 more source

Drug-Eluting Stents in Preclinical Studies [PDF]

Circulation, 2002
The arrival of drug-eluting stents raises important questions about preclinical evaluation of devices and the optimal means of predicting clinical safety and efficacy. The Interventional, Regulatory, Commercial, and Scientific communities have all asked for assistance in defining criteria for device evaluation.
Robert S, Schwartz, Elazer R, Edelman, Andrew, Carter, Nicolas, Chronos, Campbell, Rogers, Keith A, Robinson, Ron, Waksman, Judah, Weinberger, Robert L, Wilensky, Donald N, Jensen, Bram D, Zuckerman, Renu, Virmani   +11 more
openaire   +2 more sources